NCT04492033View on ClinicalTrials.gov

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 22, 2020

Primary Completion Date

January 8, 2024

Study Completion Date

January 9, 2025

Conditions
P1b: Advanced Solid TumorsP2: Biliary Tract Cancer
Interventions
DRUG

CTX-009 (ABL001)

CTX-009 (ABL001) will be administered biweekly.

DRUG

Paclitaxel

Paclitaxel will be administered weekly.

DRUG

Irinotecan

Irinotecan will be administered biweekly.

Trial Locations (4)

Unknown

Seoul National University Bundang Hospital, Seongnam-si

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Handok Inc.
All Listed Sponsors
collaborator

Compass Therapeutics

INDUSTRY

collaborator

ABL Bio, Inc.

INDUSTRY

lead

Handok Inc.

INDUSTRY

NCT04492033 - A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | Biotech Hunter | Biotech Hunter